DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

FDA clears the Arterys Oncology AI suite Designed for liver MR and CT and lung CT

Tomo associated with fewer false positives than digital mammo, study finds To be presented at ARRS annual meeting

Congress freezes radiation treatment payment rates for free-standing clinics through 2019 ASTRO applauds

For this cancer, proton therapy is no better than IMRT For treating NSCLC, the cutting edge option may not yield better outcomes

Study finds PSMA PET/CT can identify early prostate cancer recurrence Already a standard in Europe

RaySearch to supply RayStation to first proton therapy center in India Set to begin treating patients in September 2018

New paper brings attention to heart disease risk associated with breast cancer treatment Especially affects those over 65

SCOUT Radar Localization System in use at 230 U.S. hospitals Cianna Medical system has been used for over 25,000 breast tumor localizations

Varian acquires Mobius Medical Systems Will expand the company's QA software portfolio

Xstrahl releases RADiant therapy system in the U.S. Treats non-melanoma skin cancers, keloids and superficial lesions

The University of Virginia Health System
is conducting the first clinical trial
that combines focused ultrasound and
immunotherapy

Clinical trial combining focused ultrasound and immunotherapy underway

by John R. Fischer , Staff Reporter
A first-of-its-kind trial seeks to combine two forms of therapy for the treatment of stage IV breast cancer.

Researchers at the University of Virginia (UVA) Health System are conducting a clinical trial that combines noninvasive focused ultrasound technology through the use of Theraclion’s Echopulse system with an immunotherapy medication, pembrolizumab.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



“The idea behind focused ultrasound is that it’s a way to do surgery without incisions,” Patrick Dillon, associate professor of hematology and oncology at UVA, told HCB News. “In this case, it has been shown to exhibit a degree of immune recognition of tumors. The pembrolizumab is a PD-1 inhibiting antibody, which essentially means that it kind of takes the brakes off the immune system, thereby allowing for greater immune recognition of disease cells or cancer cells in this case.”

The immune system does not recognize most breast cancers as foreign cells, and therefore, does not trigger immune responses to combat them. Immunotherapy has also historically been more successful in treating other forms of cancer, compared to breast.

The aim of the trial is to observe if the combined use of focused ultrasound and pembrolizumab will enhance the ability of the immune system to recognize tumors in fifteen women participants who have been randomized to receive the medication before or following focused ultrasound treatment. Using an ultrasound probe of the Echopulse system, researchers will apply thermal energy to a target, physically heat up, and destroy up to fifty percent of the tumor.

The idea, according to Dillon, is that the ultrasound will expose some of the protein antigens to the dendritic cells of the immune system, triggering an immune response from the tumor at the same time that the tumor cells are destroyed. The addition of the pembrolizumab will allow the ultrasound to enhance immune recognition of the tumor locally in the breast and more importantly, of cancer cells in the rest of the body.

Dillon says that though it is too early to predict the results of the trial, he is optimistic in the insight it will provide on the immunological treatment of breast cancer.

“I expect that we would see at least additive if not synergistic response to this combination therapy,” he said. That’s our primary endpoint, to look specifically at the types of T cells infiltrating in the tumor. We’re looking to see if we are augmenting the T cell response, the immune response in the tumor site.”

Theraclion recently chose EDAP TMS SA to distribute the Echopulse system, which is CE-marked for treating breast fibroadenomas, thyroid nodules and other conditions, throughout France.

The system is not yet FDA approved. Pembrolizumab is not either, and is considered investigational for the purpose of the study.

The trial is currently underway and is funded, in part, by the Focused Ultrasound Foundation and the Commonwealth of Virginia. Researchers are currently looking for enrollees for the next year.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED